Computer-Assisted Decision Systems in Radiology

TriMed Staff | | Health Imaging | Screening
Computer-Assisted Decision (CAD) Systems in Radiology—The Hope, the Hype, and the Hard Truth: CAD Evaluation Issues

Monday, Nov. 29, 8:30 AM – 10:00 AM

The session is addressing clinical and technical evaluation issues to help attendees better understand nuances and limits of CAD, diving into statistics with an overview and tips for interpreting clinical study methodologies and offering the FDA’s perspective on CAD and standalone and reader performance testing.

Speaker Information:
  • Nico Karssemeijer, PhD, University Nijmegen Medical Centre in Nijmegen, the Netherlands;
  • Robert M. Nishikawa, PhD, University of Chicago Medical Center; and
  • Nicholas Petrick, PhD, deputy director of the image analysis laboratory, FDA.

TriMed Staff

Related Content

Routine abdominal CTs offer insight into cardiovascular risk
Screening efforts have helped avert millions of cancer-related deaths in recent decades
What breast density status can tell us about cardiovascular risk
FDA clears AI tool that flags signs of heart disease in chest CT scans
Patients without PCPs struggle to access lung cancer screening, despite eligibility
Breast cancer rates among women in their 30s are on the rise

Around the web

Radiology Business
The biggest challenges facing radiology business managers in 2025

RBMA President Peter Moffatt discusses some of the biggest obstacles facing the specialty in the new year. 

Cardiovascular Business
New cardiac prevention paradigm explored in TRANSFORM trial using AI and CCTA

Deepak Bhatt, MD, director of the Mount Sinai Fuster Heart Hospital and principal investigator of the TRANSFORM trial, explains an emerging technique for cardiac screening: combining coronary CT angiography with artificial intelligence for plaque analysis to create an approach similar to mammography.

Cardiovascular Business
Cardiology practices pay $17.7M to settle fraud allegations brought on by whistleblowers

A total of 16 cardiology practices from 12 states settled with the DOJ to resolve allegations they overbilled Medicare for imaging agents used to diagnose cardiovascular disease.